TP53, ATRX and RB1 mutations were equally represented in primary tumors and metastases, while PTEN alterations were more frequently observed in metastases than in primary lesions (p = 0.023), consistent with a later acquisition during tumor progression (Figure 2C). Here, TP53 is linked to neoplasm.